To determine if newer influenza vaccines can safely improve seroprotection rates of older
adults, we compared three licensed trivalent inactivated vaccines (TIVs) in a randomized …

Background During development of an A/H1N1 pandemic influenza vaccine, this study was
performed to identify the antigen and adjuvant content which would provide optimal antibody …

Objectives MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal
influenza vaccines have been developed to protect the elderly at high risk of severe …

Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …

Background. Effective planning and preparedness against a possible future A/H5N1
influenza pandemic is a major global challenge. Because dose sparing strategies are …

Background Standard‐dose seasonal influenza vaccines often produce modest
immunogenic responses in adults≥ 65 years old. MF59 is intended to elicit a greater …

Background Influenza remains a significant problem in elderly despite widespread
vaccination coverage. This randomized, phase-I study in elderly compared different …

Importance of the field: Vaccination is universally considered as the most effective tool for
the prevention of influenza, which represents a significant burden, both from a health-care …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Background A new vaccine,“Multimeric-001”(M-001) has been recently developed,
containing conserved, common linear influenza epitopes that activate both cellular and …